GLP-1 / Incretin Therapy (Semaglutide & Tirzepatide)

Clinically supervised GLP-1 receptor agonist and dual incretin therapy for weight management and metabolic health. Dr Linsey Gani prescribes semaglutide and tirzepatide with evidence-based dose titration and specialist monitoring.

LG Endocrinology offers specialist-prescribed incretin-based therapy for weight management, one of the most clinically validated pharmacological approaches for obesity available in Singapore. Dr Linsey Gani, a Fellow of the Royal Australian College of Physicians (Endocrinology) and the Academy of Medicine Singapore, prescribes and monitors these medications within a structured medical framework — not as a standalone cosmetic injection service. Semaglutide (a GLP-1 receptor agonist) works by slowing gastric emptying, reducing appetite, and improving insulin sensitivity, achieving up to 15% body weight reduction in clinical trials. Tirzepatide, a dual GIP/GLP-1 receptor agonist (the active ingredient in Mounjaro), offers enhanced metabolic effects with up to 23% weight reduction demonstrated in the SURMOUNT programme. Treatment begins with a full endocrine and metabolic assessment to confirm suitability — patients with type 2 diabetes, insulin resistance, PCOS, or metabolic syndrome are often the best candidates. Dose titration follows evidence-based protocols to minimise gastrointestinal side effects (nausea, vomiting, constipation), with regular follow-up appointments to assess response, tolerance, and progress. The clinic's endocrinologist background means that co-existing conditions such as thyroid disease, adrenal disorders, or dyslipidaemia can be co-managed within the same care pathway. Medication costs are in addition to consultation fees; prices reflect Singapore retail availability of semaglutide and tirzepatide. This is a specialist-level service appropriate for patients who have not achieved sufficient results through lifestyle modification alone and who meet clinical criteria for pharmacotherapy.